SCHEMBL2277535

SCHEMBL2277535

COCCNC(=O)c1cccc(/C=C/C(=O)c2c(O)c3ccccc3[nH]c2=O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.49
KMT2A Q03164 7/20 0.49
USP2 O75604 1/20 0.48
KDM4E B2RXH2 6/20 0.47
RAB9A P51151 6/20 0.47
NPC1 O15118 5/20 0.47
PKM P14618 1/20 0.47
PADI4 Q9UM07 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NLRP3 Q96P20 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44
ASAH1 Q13510 1/20 0.44
FGFR1 P11362 1/20 0.44
PDGFRA P16234 1/20 0.44
FLT1 P17948 1/20 0.44
KDR P35968 1/20 0.44
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
XBP1 P17861 1/20 0.44
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277539 1.00 MEN1 (0.49) MEN1KMT2AUSP2KDM4ERAB9A
SCHEMBL2279527 0.90 PADI4 (0.53) MEN1KMT2AUSP2KDM4ERAB9A
SCHEMBL2279523 0.90 PADI4 (0.53) MEN1KMT2AUSP2KDM4ERAB9A
SCHEMBL2284461 0.89 KDM4E (0.47) MEN1KMT2AUSP2KDM4ERAB9A
SCHEMBL2284456 0.89 KDM4E (0.47) MEN1KMT2AUSP2KDM4ERAB9A
SCHEMBL4512628 0.87 PADI4 (0.43) MEN1KMT2APADI4FGFR1PDGFRA
SCHEMBL4512621 0.87 PADI4 (0.43) MEN1KMT2APADI4FGFR1PDGFRA
SCHEMBL2278946 0.86 KDM4E (0.48) MEN1KMT2AUSP2KDM4ERAB9A
SCHEMBL2278941 0.86 KDM4E (0.48) MEN1KMT2AUSP2KDM4ERAB9A
SCHEMBL4510066 0.85 NPC1 (0.61) MEN1KMT2AKDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 MEN1 3520/4885KMT2A 3569/4885USP2 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.